Research programme: schizophrenia therapy - Galenea

Drug Profile

Research programme: schizophrenia therapy - Galenea

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Galenea
  • Class Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cognition disorders; Schizophrenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cognition-disorders in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Schizophrenia in USA
  • 01 May 2012 Galenea receives funding from the Stanley Medical Research Institute for its pro-congnitine drug discovery programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top